REGULATORY
Japan PM Asks Health Minister to Reform Pricing of Potential Blockbusters
Japanese Prime Minister Fumio Kishida on September 27 instructed Health Minister Keizo Takemi to consider reforming the pricing scheme for drugs with a potentially immense market in light of the recent approval of Eisai’s Alzheimer’s disease therapy Leqembi (lecanemab). The…
To read the full story
Related Article
- Japan’s New Economic Package to Include Dementia Measures: PM
October 16, 2023
REGULATORY
- DPP Calls for End to Off-Year Drug Price Cuts, Chuikyo Reform
June 15, 2026
- Pharma Wages Multi-Front Lobbying amid Push for Leaner Honebuto
June 12, 2026
- Many Approved AGs Remain Unlisted Despite Final Pre-Reform Opportunity
June 12, 2026
- iPark CEO Calls for National AI Drug Discovery Platform at LDP Hearing
June 12, 2026
- MHLW Official Urges Proper IRB Selection under New GCP Rules
June 12, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





